Findings in mice indicate that the immunomodulating lysine deacetylase inhibitors might be effective for treating patients with type 1 diabetes mellitus (T1DM). Addition of the lysine deacetylase inhibitors vorinostat and givinostat to the drinking water of nonobese diabetic mice at low doses markedly reduced diabetes incidence and counteracted inflammatory cell damage. These effects were mediated through hyperacetylation of transcription factors, which prevented transcription factor binding and reduced proinflammatory gene expression in leucocytes and β cells.
References
Christensen, D. P. et al. Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection. Proc. Natl Acad. Sci. USA 10.1073/pnas.1320850111
Rights and permissions
About this article
Cite this article
Efficacy of lysine deacetylase inhibitors in T1DM. Nat Rev Endocrinol 10, 190 (2014). https://doi.org/10.1038/nrendo.2014.6
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2014.6
